Clinical Trial Detail

NCT ID NCT04199104
Title A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010) (LEAP-10)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

laryngeal squamous cell carcinoma

oropharynx cancer

oral squamous cell carcinoma

hypopharynx cancer

Therapies

Lenvatinib + Pembrolizumab

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.